UY29119A1 - Tratamiento de esclerosis multiple - Google Patents

Tratamiento de esclerosis multiple

Info

Publication number
UY29119A1
UY29119A1 UY29119A UY29119A UY29119A1 UY 29119 A1 UY29119 A1 UY 29119A1 UY 29119 A UY29119 A UY 29119A UY 29119 A UY29119 A UY 29119A UY 29119 A1 UY29119 A1 UY 29119A1
Authority
UY
Uruguay
Prior art keywords
multiple sclerosis
mammal
bodies
liposomes
sclerosis treatment
Prior art date
Application number
UY29119A
Other languages
English (en)
Inventor
Marina Anetta Lynch
Yvonne Mairead Nolan
Anthony Ernest Bolton
Mandel Arkady
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of UY29119A1 publication Critical patent/UY29119A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Administración a un mamífero de pequenas dosis de cuerpos, tal como liposomas, de un tamano semejante al de las células de mamífero. Dichos cuerpos presentan grupos principales de glicerol fosfato sobre sus superficies externas, y afectan benéficamente los síntomas, que incluyen correlatos bioquímicos de esclerosis múltiple (MS) en dicho mamífero. Se prefieren los liposomas compuestos de 50-100% de fosfatidilglicerol, donde los grupos principales de fosfoglicerol se encuentran en la superficie externa.
UY29119A 2004-09-15 2005-09-15 Tratamiento de esclerosis multiple UY29119A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE20040613 2004-09-15

Publications (1)

Publication Number Publication Date
UY29119A1 true UY29119A1 (es) 2006-05-31

Family

ID=35207670

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29119A UY29119A1 (es) 2004-09-15 2005-09-15 Tratamiento de esclerosis multiple

Country Status (9)

Country Link
US (1) US20060105032A1 (es)
EP (1) EP1793833A1 (es)
AR (1) AR052642A1 (es)
CA (1) CA2578248A1 (es)
EA (1) EA200700626A1 (es)
PE (1) PE20060661A1 (es)
TW (1) TW200616645A (es)
UY (1) UY29119A1 (es)
WO (1) WO2006029886A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563022B2 (en) * 2006-10-11 2013-10-22 Board Of Regents Of The University Of Texas System Particles for cell targeting
AU2008232677B2 (en) 2007-03-29 2013-09-19 National Jewish Health Surfactant lipids, compositions thereof, and uses thereof
US8173115B2 (en) * 2008-07-29 2012-05-08 The Board Of Regents Of The University Of Texas System Particle compositions with a pre-selected cell internalization mode

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303719A2 (hu) * 2000-10-16 2004-03-01 Neopharm, Inc. Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra
IL155696A0 (en) * 2000-11-09 2003-11-23 Neopharm Inc Sn-38 lipid complexes and methods of use
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response

Also Published As

Publication number Publication date
TW200616645A (en) 2006-06-01
EP1793833A1 (en) 2007-06-13
AR052642A1 (es) 2007-03-28
WO2006029886A1 (en) 2006-03-23
PE20060661A1 (es) 2006-09-16
EA200700626A1 (ru) 2007-10-26
US20060105032A1 (en) 2006-05-18
CA2578248A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
CO6270192A2 (es) Utensiliopara el cuidado oral que tiene un inserto en la cabeza
AR095696A2 (es) Panel de yeso liviano
ES2572160T3 (es) Una nueva preparación farmacéutica para preeclampsia
ECSP056234A (es) Boquilla microestructurada de alta presión con función de filtro incorporada
ECSP055738A (es) PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL
AR076168A1 (es) Articulo cementicio y metodo para prepararlo
SV2010003567A (es) Derivados bis-(sulfonilamino) en terapia 066
UY28514A1 (es) Nuevos compuestos
CL2008003901A1 (es) Uso de un inhibidor de hedgehog para extender la sobrevida libre de recidiva en un paciente con cancer, que se encuentra en quimioterapia o ha sido tratado previamente con quimioterapia.
DOP2010000191A (es) Derivados bis-(sulfonilamino)
ECSP21052184A (es) Inhibidores de apol1 y sus métodos de uso
UY28342A1 (es) Nuevos compuestos
BR112018003031A2 (pt) formulações clínicas
AR057785A1 (es) Tablero de tabique con propiedades antifungicas y metodo para hacer el mismo
AR034746A1 (es) Combinaciones para el tratamiento de trastornos inflamatorios
GT199700015A (es) Inhibidores de metaloproteinasa, composiciones farmaceuticas que las contienen y su uso farmaceutico y metodosyeficazproducto intermedio para su preparacion.
GT200800063A (es) Compuestos para la inhibicion de enzimas
UY29878A1 (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
NI201000079A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrófilos.
AR046970A1 (es) Esteres de fosfato de florfenicol
AR063570A1 (es) Efectos biologicos mejorados para composiciones que comprenden acido rosmarinico
UY29119A1 (es) Tratamiento de esclerosis multiple
CL2018002431A1 (es) Panel tipo sándwich con aberturas
ES2051675T3 (es) Inhibidores de protorfirinogeno y su uso en composiciones para detectar y tratar tumores.
CO2018002198A2 (es) Composiciones farmacéuticas que comprenden un compuesto oligomérico para modular la expresión de apolipoproteína (a)